The U.S. Food and Drug Administration simply approved bremelanotide as a brand new pharmaceutical treatment plan for pre-menopausal females with low libido. Marketed underneath the name brand Vyleesi, the medication that is injectable utilized to deal with exactly exactly just what happens to be referred to as hypoactive sexual interest disorder (HSDD). It’s the 2nd libido-enhancing medicine on the marketplace for females. (the very first, Addyi, ended up being authorized in 2015 and it is a once-a-day tablet made to increase libido.)